Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort study

To compare safety, visual acuity (VA), and anatomic outcomes of 2.5 mg/kg and 5 mg/kg intravenous bevacizumab in patients with neovascular age-related macular degeneration. In an institutional cohort study, 16 patients (2 cohorts, 27 eyes) with neovascular age-related macular degeneration were treat...

Full description

Saved in:

Bibliographic Details
Published in:	Retina (Philadelphia, Pa.) Vol. 28; no. 10; pp. 1375 - 1386
Main Authors:	Geitzenauer, Wolfgang, Michels, Stephan, Prager, Franz, Rosenfeld, Philip J, Kornek, Gabriela, Vormittag, Laurenz, Schmidt-Erfurth, Ursula
Format:	Journal Article
Language:	English
Published:	United States 01-11-2008
Subjects:	Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Blood Pressure Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Female Fluorescein Angiography Humans Infusions, Intravenous Macular Degeneration - complications Macular Degeneration - drug therapy Male Middle Aged Prospective Studies Time Factors Tomography, Optical Coherence Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!